UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and MGFA Scientific Session

UCB will contribute 14 presentations, including an oral presentation, selected to feature across the AANEM and MGFA meeting, emphasizing UCB's leadership in neuromuscular research
Presentations showcase new data for UCB’s gMG treatments, including post hoc analyses highlighting long-term safety and efficacy for ZILBRYSQ^®▼ (zilucoplan)^1,2  and RYSTIGGO^®▼ (rozanolixizumab)^3,4 
 

Brussels (Belgium), 11 Oct 2024: 07:00 (CET) - UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that it will be presenting results from across its portfolio in generalized myasthenia gravis (gMG) at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) annual meeting and the Myasthenia Gravis Foundation of America (MGFA) Scientific Session taking place between October 15 - 18, 2024 at the Savannah Convention Center in Georgia, U.S.

A total of 14 abstracts, including one oral presentation, will feature data from studies of UCB’s recently approved medicines for the treatment of gMG, RYSTIGGO^®▼ and ZILBRYSQ^®▼, along with findings from real-world studies of clinical outcomes and patient experience in gMG. 

“At UCB, we are committed to transforming the lives of those living with generalized myasthenia gravis through ongoing innovation and comprehensive clinical research”, commented Manuela Maronati, Global Asset Head, Neuroimmunology & Rare. “Our presentations at the 2024 AANEM Annual Meeting and MGFA Scientific Session underscore our dedication to advancing understanding and treatment of this challenging condition. We are particularly excited to share insights from our RAISE-XT and MycarinG studies, which reflect significant progress in the management of generalized myasthenia gravis.”

Key UCB scientific and real-world data to be presented at AANEM and the MGFA Scientific Session include: 

• An oral presentation focusing on UCB’s innovative work on enhancing global education standards for myasthenia gravis.⁵
• Phase 3b study results on switching to subcutaneous zilucoplan from IV complement component 5 inhibitors in myasthenia gravis.⁶ 
• Data from the RAISE-XT trial for zilucoplan - including an interim analysis of long-term safety and efficacy over a period of up to 120 weeks, compliance to daily self-administered subcutaneous zilucoplan, and a post-hoc analysis of corticosteroid sparing and non-steroidal immunosuppressant therapy changes up to 120 weeks - offering new insights into the management potential for generalized myasthenia gravis in a clinical setting.^7,8,9
• For rozanolixizumab, post hoc analyses from the Phase 3 MycarinG trial in patients with generalized myasthenia gravis describe the impact of treatment on specific muscle group weaknesses, evaluate rozanolixizumab in those aged 65 years and older, and highlight its use for individualized treatment regimens.^10,11,12

UCB will also host an industry-sponsored therapeutic update session on an expert-led discussion on generalized myasthenia gravis treatment choices on October 16, 2024.

“At this year's AANEM Annual Meeting and MGFA Scientific Session, we are proud to share data from UCB’s innovative work, which is advancing the standard of education for generalized myasthenia gravis globally. This program not only underscores our dedication to empowering healthcare professionals with knowledge and tools but also highlights our ongoing commitment to addressing the complex challenges faced by the MG community," commented Emmanuel Caeymaex, Executive Vice President, Head of Patient Impact, UCB. "

UCB presentations during AANEM and MGFA 2024

Additionally, for registered healthcare professionals, UCB has arranged for a program of sponsored scientific and therapeutic updates. Visit us at our booth for more information.